Skip to main content

09-19-2019 | Medications | Video | Article

Expert commentary: Trial results of imeglimin in type 2 diabetes

John Wilding comments on study results highlighting that imeglimin, an agent targeting mitochondrial bioenergetics, may represent a novel therapeutic approach for type 2 diabetes (2:17).

Receive weekly updates on the diabetes news that matters to you

Read the interview transcript

Back to the EASD 2019 conference hub

Related topics

Related content